Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-02-06
2007-02-06
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S179000
Reexamination Certificate
active
11074037
ABSTRACT:
This invention relates to the use of temozolomide esters (4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxylate esters) Formula 1 as potent anticancer pro-drugs for treatment of cancers by topical and transdermal applications, and to a novel process for synthesis of temozolomide esters by a direct esterification of temozolomide acid (3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxylic acid) with a halogeno-aliphatic compound in presence of a base, or with an alcohol in presence of a dehydrate agent
REFERENCES:
patent: 5260291 (1993-11-01), Lunt et al.
patent: 1485327 (2004-03-01), None
patent: 0 252 682 (1988-01-01), None
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition,vol. 1, 1004-1010, 1996.
Vippagunta et al., Advanced Drug Delivery Reviews 48: 3-26, 2001.
Payne et al. Critical Reviews in Oncology/Hematology 53, 241-252, 2005.
Wang et al., CN 1485327, CA 142: 392443, 2005.
Beall, Howard D. and Sloan, Kenneth B.: International Journal of Pharmaceutics,Topical delivery of 5-fluorouracil(5-FU)by 1,3-bisalkylcarbonyl-5-FU prodrugs, vol. 231, pp. 43-49 (2002).
Bleehen, N. M., et al.: Journal of Clinical Oncology,Cancer Research Campaign Phase II Trial of Temozolomide in Metastatic Melanoma, vol. 13, No. 4, pp. 910-913 (Apr. 1995).
Bodor, N. and Sloan, K. B.: Department of Medicinal Chemistry, University of Florida,Improved delivery through biological membranes XII. The effect of the incorporation of biphasic solubilizing groups into prodrugs of steroids, pp. 235-250 (1982).
Bronaugh, Robert L. and Maibach, Howard I.:in vitro percutaneous absorption, Chapter 4, pp. 121-133.
Transdermal Drug Delivery and Delivery Systems, Chapter 7, pp. 301-380.
Diez-Sales, O., et al.: International Journal of Pharmaceutics,The prediction of percutaneous absorption: I. Influence of the dermis on in vitro permeation models, vol. 100, pp. 1-7 (1993).
Gajewski, Thomas F.: Journal of Clinical Oncology,Temozolomide for Melanoma: New Toxicities and New Opportunities, vol. 22, No. 4, pp. 580-581 (Feb. 15, 2004).
Heimberger, Amy B., et al.: Clinical Cancer Research,Temozolomide Delivered by Intracerebral Microinfusion is Safe and Efficacious Against Malignant Gliomas in Rats, vol. 6, pp. 4148-4153 (Oct. 2000).
Flynn, Gordon L., et al.: In Vitro Transport,Transdermal Delivery of Drugs, Chapter 4, vol. 1, pp. 45-59; and Wester, Ronald C. and Malbach, Howard I: Animal Models for Transdermal Delivery, Chapter 5, vol. 1, pp. 61-83.
Hotchkiss, Sharon A. M.: Imperial College School of Medicine, London, England,Dermal Metabolism, Chapter 2, pp. 43 to 101.
Hotchkiss, Sharon A. M.: Imperial College School of Medicine, London, England,Skin as xenobiotic metabolizing organ, Chapter 6, pp. 217-262.
Behrendt, H. and Kampffmeyer, H. G.: XENOBIOTICA,Absorption and ester cleavage of methyl salicylate by skin of single-pass perfused rabbit ears, vol. 19, No. 2, pp. 131-141 (1989).
Lopez, A., et al.: International Journal of Pharmaceutics,Skin permeation model of phenyl alcohols: comparison of experimental conditions, vol. 173, pp. 183-191 (1998).
Maenpaa, Juhani, et al.: Cancer Chemotherapy and Pharmacology,Topical toremifene: a new approach for cutaneous melanoma?, vol. 32, pp. 392-395 (1993).
Middleton, M. R., et al.: Journal of Clinical Oncology,Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma, vol. 18, No. 1, pp. 158-166 (Jan. 2000).
Mosmann, Tim: Journal of Immunological Methods,Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays, vol. 65, pp. 55-63 (1983).
Rathbone, D. L., et al.: Journal of Pharmaceutical Pharmacology,Soluble prodrugs of the anticancer drugs temozolomide and mitozolomide, Appendix I, vol. 51 (Supplement), No. 26, p. 111 (1999).
Raymond, Eric, et al.: Clinical Cancer Research,Activity of Temozolomide against Human Tumor Colony-Forming Units, vol. 3, pp. 1759-1774 (Oct. 1997).
Sampson, John H., et al.: Clinical Cancer Research,Treatment of Neoplastic Meningitis with Intrathecal Temozolomide, vol. 5, pp. 1183-1188 (May 1999).
Soe, Lin, et al.: Cancer Chemotherapy and Pharmacology,Tissue distribution of transdermal toremifene, vol. 39, pp. 513-520 (1997).
Stevens, Malcolm F. G., et al.: Journal of Medicinal Chemistry,Antitumor Imidazotetrazines. . . , vol. 27, No. 2, pp. 196-201 (1984).
Stevens, Malcolm F. G., et al.: Cancer Research,Antitumor Activity and Pharmacokinetics of CCRG 81045, vol. 47, pp. 5846-5852 (Nov. 15, 1987).
Su, Y. B., et al.: Journal of Clinical Oncology,Selective CD4+ Lymphopenia in Melanoma Patients Treated With Temozolomide: A Toxicity With Therapeutic Implications, vol. 22, No. 4, pp. 610-616 (Feb. 15, 2004).
Tsang, Lincoln L. H., et al.: Cancer Chemotherapy and Pharmacology,Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-I-yl)imidazole-4-carboxamide, vol. 27, pp. 342-346 (1991).
Tsang, Lincoln L. H., et al.: Cancer Chemotherapy and Pharmacology,Characterization of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity, vol. 26, pp. 429-436 (1990).
Valia, Kirti H., et al., Drugs Development and Industrial Pharmacy,Long-Term Permeation Kinetics of Estradiol:(III)Kinetic Analyses of the Simultaneous Skin Permeation and Bioconversion of Estradiol Esters, vol. 11, No. 6&7, pp. 1133-1173 (1985).
Wang, Yongfeng, et al.: Journal of Organic Chemistry,Antitumor Imidazotetrazines. 35. New Synthetic Routes to the Antitumor Drug Temozolomide, vol. 62, pp. 7288-7294 (1997).
Leo, Albert, et al.: Chemical Reviews,Partition Coefficients and Their Uses, vol. 71, No. 6, pp. 525-554 (Dec. 1971).
Conway Barbara R.
Suppasansatorn Panassaya
Wang Yongfeng
Balasubramanian Venkataraman
Galletta Elizabeth A.
Garabedian Todd E.
Tianjin North Pharm Sci-Tech Co., Ltd.
Wiggin and Dana LLP
LandOfFree
Synthesis of temozolomide esters as potent anticancer... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synthesis of temozolomide esters as potent anticancer..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthesis of temozolomide esters as potent anticancer... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3829923